TN2011000218A1 - Aryl piperazine and their use as alpha2c antagonists - Google Patents

Aryl piperazine and their use as alpha2c antagonists

Info

Publication number
TN2011000218A1
TN2011000218A1 TN2011000218A TN2011000218A TN2011000218A1 TN 2011000218 A1 TN2011000218 A1 TN 2011000218A1 TN 2011000218 A TN2011000218 A TN 2011000218A TN 2011000218 A TN2011000218 A TN 2011000218A TN 2011000218 A1 TN2011000218 A1 TN 2011000218A1
Authority
TN
Tunisia
Prior art keywords
aryl piperazine
alpha2c
alpha2c antagonists
antagonists
piperazine
Prior art date
Application number
TN2011000218A
Other languages
English (en)
Inventor
Patrik Holm
Arto Tolvanen
Gerd Wohlfahrt
Belle David Din
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of TN2011000218A1 publication Critical patent/TN2011000218A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000218A 2008-11-20 2011-05-05 Aryl piperazine and their use as alpha2c antagonists TN2011000218A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19335508P 2008-11-20 2008-11-20
PCT/FI2009/000097 WO2010058060A1 (fr) 2008-11-20 2009-11-20 Arylpipérazines et leur emploi en tant qu'antagonistes de alpha2c

Publications (1)

Publication Number Publication Date
TN2011000218A1 true TN2011000218A1 (en) 2012-12-17

Family

ID=41490335

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000218A TN2011000218A1 (en) 2008-11-20 2011-05-05 Aryl piperazine and their use as alpha2c antagonists

Country Status (21)

Country Link
US (1) US20110262352A1 (fr)
EP (1) EP2364303A1 (fr)
JP (1) JP5513515B2 (fr)
KR (1) KR20110086747A (fr)
CN (1) CN102216282A (fr)
AR (1) AR074204A1 (fr)
AU (1) AU2009317117A1 (fr)
BR (1) BRPI0921669A2 (fr)
CA (1) CA2741986A1 (fr)
CO (1) CO6382156A2 (fr)
EA (1) EA201170711A1 (fr)
GE (1) GEP20135959B (fr)
IL (1) IL212571A0 (fr)
MA (1) MA32818B1 (fr)
MX (1) MX2011005367A (fr)
NZ (1) NZ592571A (fr)
TN (1) TN2011000218A1 (fr)
TW (1) TW201024282A (fr)
UA (1) UA105647C2 (fr)
WO (1) WO2010058060A1 (fr)
ZA (1) ZA201103462B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
PE20160842A1 (es) * 2013-12-19 2016-09-24 Bayer Pharma AG Piperidiniltetrahidroquinolinas sustituidas
CN106029657A (zh) * 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
CN106029648A (zh) * 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
TWI704145B (zh) * 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
EA201990158A1 (ru) 2016-06-29 2019-05-31 Орион Корпорейшн Производные бензодиоксана и их фармацевтическое применение
MA53711A (fr) 2018-09-25 2021-12-29 Bayer Ag Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil
WO2020225188A1 (fr) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft COMBINAISON D'UN ANTAGONISTE DE RÉCEPTEUR α2-ADRÉNERGIQUES DE SOUS-TYPE C (ALPHA-2C) AVEC UN BLOQUEUR DE CANAL TASK-1/3 POUR LE TRAITEMENT DE L'APNÉE DU SOMMEIL
EP3965766A1 (fr) * 2019-05-09 2022-03-16 Bayer Aktiengesellschaft Combinaison d'antagonistes d'un sous-type c de récepteur ?2-adrénergique (alpha-2c) avec un bloqueur de canal task1/3 pour le traitement de l'apnée du sommeil
CN110615774B (zh) * 2019-09-19 2022-11-11 安徽中医药大学 具有抗炎活性的苄基哌嗪类化合物、制法及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695295A (en) * 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
JPS5515456A (en) * 1978-07-19 1980-02-02 Morishita Seiyaku Kk 2-substituted-piperazinomethyl-1,4-benzodioxane
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
WO2003029239A1 (fr) * 2001-10-04 2003-04-10 Wyeth Derives de chromane et de benzofurane utilises comme ligands 5-hydroxytryptamine-6
PL372657A1 (en) 2002-04-03 2005-07-25 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
WO2004067513A1 (fr) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonistes pour recepteurs alpha-2 adrenergiques
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物

Also Published As

Publication number Publication date
WO2010058060A1 (fr) 2010-05-27
AR074204A1 (es) 2010-12-29
NZ592571A (en) 2013-03-28
EP2364303A1 (fr) 2011-09-14
BRPI0921669A2 (pt) 2018-06-26
MA32818B1 (fr) 2011-11-01
US20110262352A1 (en) 2011-10-27
AU2009317117A1 (en) 2010-05-27
UA105647C2 (uk) 2014-06-10
JP5513515B2 (ja) 2014-06-04
CO6382156A2 (es) 2012-02-15
CN102216282A (zh) 2011-10-12
EA201170711A1 (ru) 2012-01-30
MX2011005367A (es) 2011-06-20
IL212571A0 (en) 2011-06-30
GEP20135959B (en) 2013-11-11
JP2012509302A (ja) 2012-04-19
ZA201103462B (en) 2012-01-25
KR20110086747A (ko) 2011-07-29
CA2741986A1 (fr) 2010-05-27
TW201024282A (en) 2010-07-01

Similar Documents

Publication Publication Date Title
TN2011000218A1 (en) Aryl piperazine and their use as alpha2c antagonists
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
WO2008101187A3 (fr) Pro-médicaments d'antagonistes opioïdes phénoliques périphériques
MY153872A (en) 2,3-dihydrobenzo{1,4} dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in treatment of peripheric and central nervous system diaseases
MX2010001575A (es) Derivados de 1,2-diamido-etileno como antagonistas de orexina.
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
GEP20156230B (en) Forms of rifaximin and usage thereof
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
TN2010000064A1 (en) Novel herbicides
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX2009009774A (es) Derivados de quinolina como fungicidas.
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
MX2007005932A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
UA107791C2 (en) Pesticidal compositions
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
MX2010002244A (es) Nuevos fungicidas.
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
MX2011007998A (es) Nuevos herbicidas.
MY161132A (en) Novel herbicides
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides